Related Experiment Video
Updated: Mar 6, 2026
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
Innovations in cardiac transplantation
Reema Hasan1, Ashraf Abou El Ela, Daniel Goldstein
1aDepartment of Internal Medicine/Cardiovascular Medicine bDepartment of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan, USA.
Purpose Of Review:
As the number of people living with heart failure continues to grow, future treatments will focus on efficient donor organ donation and ensuring safe and durable outcomes. This review will focus on organ procurement, graft surveillance and emerging therapies.
Recent Findings:
Preliminary studies into donation after cardiac death have indicated that this may be an effective means to increase the donor pool. Novel preservation techniques that include ex-vivo perfusion to improve donor metabolic stabilization prior to implantation may also expand the donor pool. Biomarkers, including circulating-free DNA, are emerging that could replace the endomyocardial biopsy for acute graft rejection, but we lack a risk predictive biomarker in heart transplantation. Novel immune suppressants are being investigated. Emerging therapeutics to reduce the development of chronic allograft vasculopathy are yet to be found.
Summary:
This review highlights the most recent studies and future possible therapies that will improve outcomes in cardiac transplantation. Larger clinical trials are currently taking place and will be needed in the future to develop and sustain current trends toward better survival rates with cardiac transplantation.
Insights
Future heart transplantation focuses on increasing organ donors through donation after cardiac death and novel preservation methods. Emerging biomarkers and therapies aim to improve graft surveillance and long-term patient outcomes.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunology
Background:
- Growing prevalence of heart failure necessitates advancements in cardiac transplantation.
- Current strategies focus on organ procurement, graft surveillance, and therapeutic outcomes.
Purpose of the Study:
- To review recent advancements in organ procurement for heart transplantation.
- To discuss emerging graft surveillance techniques and novel therapeutic strategies.
- To highlight future directions for improving cardiac transplant outcomes.
Main Methods:
- Review of preliminary studies on donation after cardiac death.
- Analysis of novel organ preservation techniques, including ex-vivo perfusion.
- Evaluation of emerging biomarkers for acute graft rejection.
- Investigation into novel immunosuppressants and therapeutics for chronic allograft vasculopathy.
Main Results:
- Donation after cardiac death shows potential to expand the donor pool.
- Ex-vivo perfusion may enhance donor organ viability.
- Circulating-free DNA is a potential biomarker for acute graft rejection, replacing endomyocardial biopsy.
- No definitive risk-predictive biomarker for heart transplantation is currently available.
- Novel immunosuppressants and therapeutics for chronic allograft vasculopathy are under investigation.
Conclusions:
- Advancements in organ procurement and preservation are crucial for expanding the donor pool.
- Biomarkers and novel therapeutics hold promise for improving graft surveillance and long-term outcomes.
- Ongoing clinical trials are essential to validate these advancements and improve survival rates in cardiac transplantation.
